Leaderboards/Advanced Breast Cancer Therapies

Advanced Breast Cancer Therapies

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
M.P. Goetz
Mayo Clinic
2
Shazia Sofi
University of Kashmir
3
Lisa Crozier
University of Dundee
4
Otto Metzger
Harvard University
5
Rania El Botty
Institut Curie
6
L. Provenzano
Fondazione IRCCS Istituto Nazionale dei Tumori
7
Andrea C. Chaikovsky
Stanford University
8
Nealia C. House
Blueprint Medicines (United States)
9
Marta Palafox
Vall d'Hebron Institute of Oncology
10
Chang-Ching Lin
Southwestern Medical Center

Papers

1
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3
Annals of Oncology|2024
206 cit.
2
Publication in Annals of Oncology (2025) [33 citations, W4409253861]
Annals of Oncology|2025
33 cit.
3
Topical retinoid drug Adapalene: A new frontier in cancer treatment
Results in Chemistry|2024
32 cit.
4
Publication in Cancer Research (2025) [22 citations, W4407520407]
Cancer Research|2025
22 cit.
5
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen
npj Breast Cancer|2025
7 cit.
6
Publication in Cancer Research (2024) [4 citations, W4393089026]
Cancer Research|2024
4 cit.
7
Publication in Annals of Oncology (2025) [1 citation, W4415279920]
Annals of Oncology|2025
1 cit.
8
Publication in ESMO Open (2024) [W4397007491]
ESMO Open|2024
0 cit.
9
Publication in Cancer Research (2025) [W4409631270]
Cancer Research|2025
0 cit.
10
Publication in theses.fr (ABES) (2025) [W4416181958]
theses.fr (ABES)|2025
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
E.P. Winer
Dana-Farber Cancer Institute
2
Julia A. Beaver
Center for Drug Evaluation and Research
3
Chanchal Goswami
AMRI Hospitals
4
Stephanie L. Graff
Providence College
5
Laurence Lousberg
Centre Hospitalier Chrétien
6
Elgene Lim
St Vincent's Hospital Sydney
7
Aimery de Gramont
Sorbonne Université
8
Stephen G. Dann
Pfizer (United States)
9
Erika Hamilton
Sarah Cannon
10
Jared L. Johnson
Harvard University

Papers

1
An atlas of substrate specificities for the human serine/threonine kinome
Nature|2023
703 cit.
2
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
The Lancet Oncology|2022
317 cit.
3
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors
Clinical Cancer Research|2022
171 cit.
4
The intrinsic substrate specificity of the human tyrosine kinome
Nature|2024
143 cit.
5
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
The Breast|2022
133 cit.
6
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Nature Medicine|2024
128 cit.
7
Rise of Antibody-Drug Conjugates: The Present and Future
American Society of Clinical Oncology Educational Book|2023
102 cit.
8
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
New England Journal of Medicine|2025
94 cit.
9
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
Future Oncology|2024
91 cit.
10
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021
JAMA Oncology|2022
80 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Dennis J. Slamon
University of California, Los Angeles
2
Aron Goldhirsch
Istituti di Ricovero e Cura a Carattere Scientifico
3
Jennifer A. Pietenpol
Vanderbilt University
4
Eric P. Winer
University of Vermont
5
Rashmi Kumar
University of London
6
Nicholas C. Turner
Institute of Cancer Research
7
William C. Wood
Eastern Cooperative Oncology Group
8
Joyce O’Shaughnessy
Baylor University Medical Center
9
Massimo Cristofanilli
Cornell University
10
José Baselga
Novartis (Switzerland)

Papers

1
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene
Science|1987
11.7k cit.
2
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
New England Journal of Medicine|2001
11.5k cit.
3
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
Science|1989
6.9k cit.
4
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Journal of Clinical Investigation|2011
5.5k cit.
5
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
New England Journal of Medicine|2004
4.6k cit.
6
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
Annals of Oncology|2011
3.9k cit.
7
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Annals of Oncology|2013
3.7k cit.
8
Pembrolizumab for Early Triple-Negative Breast Cancer
New England Journal of Medicine|2020
3.1k cit.
9
Palbociclib and Letrozole in Advanced Breast Cancer
New England Journal of Medicine|2016
2.9k cit.
10
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
New England Journal of Medicine|2011
2.8k cit.

Reagents for Advanced Breast Cancer Therapies

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

MedChemExpress

Palbociclib

Cited in 7 papers
#HY-50767
View Evidence →

⭐ Top Rated

Best all-around

NovusEvidence 68

Cdk6 Antibody [DyLight 405]

Cited in 16 papers
#NBP2-98990V
View Evidence →
NovusEvidence 68

Cdk6 Antibody [DyLight 350]

Cited in 16 papers
#NBP2-98990UV
View Evidence →
NovusEvidence 68

Cdk6 Antibody (8G3)

Cited in 16 papers
#NBP3-26663 (also NBP3-26663-100ul, NBP3-26663-50ul)
View Evidence →

🌟 All-Time

Most validated

Cell Signaling TechnologyEvidence 66

Rb (4H1) Mouse Monoclonal Antibody

Cited in 17 papers
#9309$157,883
View Evidence →
Cell Signaling TechnologyEvidence 65

Phospho-Rb (Ser807/811) (D20B12) Rabbit Monoclonal Antibody

Cited in 16 papers
#8516$1,861,043
View Evidence →
NovusEvidence 68

Cdk6 Antibody (S03-2G5)

Cited in 16 papers
#NBP3-14918 (also NBP3-14918-100ul, NBP3-14918-25ul)
View Evidence →